Yoshikawa Hiroyuki
Department of Obstetrics & Gynecology, Graduate School of Human Comprehensive Sciences, University of Tsukuba.
Gan To Kagaku Ryoho. 2010 Jun;37(6):971-5.
For cervical cancer prevention, Cervarix(HPV-16/18)was approvedin Japan andvaccination programs against HPV-16/18 were startedin December, 2009. This vaccine is almost 100% effective in preventing high-grade precancer associated with the HPV types; it is safe and well tolerated. In Japan, universal vaccination of females between 11 and 14 years is recommended. We all look forward to eradicating cervical cancer in the not too distant future.
为预防宫颈癌,希瑞适(HPV-16/18)在日本获批,针对HPV-16/18的疫苗接种计划于2009年12月启动。这种疫苗在预防与这些HPV类型相关的高级别癌前病变方面几乎100%有效;它安全且耐受性良好。在日本,建议对11至14岁的女性进行普遍接种。我们都期待在不久的将来根除宫颈癌。